1.Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests
José María PAREDES ; Tomás RIPOLLÉS ; Ángela ALGARRA ; Rafael DIAZ ; Nadia MORENO ; Patricia LATORRE ; María Jesús MARTÍNEZ ; Pilar LLOPIS ; Antonio LÓPEZ ; Eduardo MORENO-OSSET
Intestinal Research 2022;20(3):361-369
Background/Aims:
Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn’s disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.
Methods:
Patients with exclusively ileal involvement CD who underwent IUS and an FC were prospectively included. Simple ultrasound index was used to determine inflammatory activity. The usual statistical tests for comparison of diagnostic techniques were used.
Results:
One hundred and five patients were included, IUS showed inflammatory activity in 59% of patients and complications in 18.1%. FC showed a significant correlation with IUS in the weak range (Spearman coefficient r=0.502; P<0.001); the area under the receiver operating characteristic curve was 0.79 (95% confidence interval, 0.70–0.88; P<0.001). The FC value that best reflected the activity in IUS was 100 μg/g with sensitivity, specificity, and positive and negative predictive values of 73.0%, 71.4%, 79.3% and 63.8%, respectively. There were no differences in FC concentration between patients with or without transmural complications. The addition of serum C-reactive protein to FC did not improve the ability to assess IUS activity.
Conclusions
FC has a significant correlation with IUS to monitor ileal CD activity. This correlation is weak and it does not allow assessing the presence of CD complications. Both tests should be used in conjunction for tight control of ileal CD. More studies on noninvasive tests in this location are needed.
2.Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Belen LOPEZ-MILLAN ; Rafael DIAZ DE LA GUARDIA ; Heleia ROCA-HO ; Carmen M GARCÍA-HERRERO ; Jessie R LAVOIE ; Michael ROSU-MYLES ; Elena GONZALEZ-REY ; Francisco O'VALLE ; Gabriel CRIADO ; Mario DELGADO ; Pablo MENENDEZ
Experimental & Molecular Medicine 2017;49(2):e290-
Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases.
Arthritis, Experimental
;
Arthritis, Rheumatoid*
;
Cytokines
;
Dextran Sulfate
;
Humans
;
In Vitro Techniques
;
Inflammatory Bowel Diseases*
;
Lymphocytes
;
Models, Theoretical*
;
Thalidomide
;
Therapeutic Uses
3.Project Hawkeye: A cross-sectional study on the prevalence of undetected refractive errors in schoolage children
Gabrielle Delos H. Reyes ; Jan Erik B. Detran ; Maria Immanuelle C. Devela ; Khia Cates N. Devoma ; Miguel Enrico D. Dial ; Jurish Candice E. Diaz ; Rafael Jose A. Dimaculangan ; Alejandro S. Dizon Jr. ; Dean Marco R. Dizon ; Patricia Mae F. Domingo ; Banette Lysa F. Estacio ; Remigio Jay-Ar Z. Butacan IV ; Fay Charmaine S. Cruz
Health Sciences Journal 2017;6(2):69-75
Introduction:
In the Philippines, essential eye care services are not easily accessible especially
for those in lower income groups, putting public elementary school students at risk for underdiagnosis of problems in visual acuity. The objective of this investigation was to determine
prevalence of undetected refractive errors among public elementary students using the Welch Allyn
Spot™ Vision Screener.
Methods :
A cross-sectional design was used in this investigation to estimate the prevalence of
uncorrected refractive errors in the first grade students in San Perfecto Elementary School using
Welch Allyn Spot™ Vision Screener (Photoscreener). Eligible students who gave informed consent
and assent answered a questionnaire and underwent an eye examination. The prevalence of
undetected errors of refraction were computed for the sample population and for selected demographic
variables.
Results :
Approximately one out of four students (24.53%) had errors of refraction, with the most
common type being astigmatism (22.64%), followed by myopia (3.77%) and hyperopia (2.83%).
Conclusion
This study revealed a high prevalence of undetected refractive errors among school-age
children, higher than current published data (5%) in the Philippines.
Cross-Sectional Studies
;
Refractive Errors
4.Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)
Martin J. O’DONNELL ; Matthew MCQUEEN ; Allan SNIDERMAN ; Guillaume PARE ; Xingyu WANG ; Graeme J. HANKEY ; Sumathy RANGARAJAN ; Siu Lim CHIN ; Purnima RAO-MELACINI ; John FERGUSON ; Denis XAVIER ; Liu LISHENG ; Hongye ZHANG ; Prem PAIS ; Patricio LOPEZ-JARAMILLO ; Albertino DAMASCENO ; Peter LANGHORNE ; Annika ROSENGREN ; Antonio L. DANS ; Ahmed ELSAYED ; Alvaro AVEZUM ; Charles MONDO ; Conor JUDGE ; Hans-Christoph DIENER ; Danuta RYGLEWICZ ; Anna CZLONKOWSKA ; Nana POGOSOVA ; Christian WEIMAR ; Romana IQBAL ; Rafael DIAZ ; Khalid YUSOFF ; Afzalhussein YUSUFALI ; Aytekin OGUZ ; Ernesto PENAHERRERA ; Fernando LANAS ; Okechukwu S. OGAH ; Adesola OGUNNIYI ; Helle K. IVERSEN ; German MALAGA ; Zvonko RUMBOLDT ; Shahram OVEISGHARAN ; Fawaz AL HUSSAIN ; Yongchai NILANONT ; Salim YUSUF ;
Journal of Stroke 2022;24(2):224-235
Background:
and Purpose The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes.
Methods:
Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH).
Results:
Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001).
Conclusions
The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.